ArticleScientific reports2019

Patients with III and IV category of the Bethesda System under levothyroxine non-suppressive therapy have a lower rate of thyroid malignancy.

Krzysztof Kaliszewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.